UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2011
Commission File Number: 001-31368
SANOFI-AVENTIS
(Translation of registrant’s name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
In April 2011, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 to 99.5 which are incorporated herein by reference.
Exhibit List
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press release dated April 5, 2011: Data from Two Mipomersen Phase 3 Trials Presented at ACC | |
| Exhibit 99.2 | Press release dated April 7, 2011: Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy of Neurology | |
| Exhibit 99.3 | Press release dated April 8, 2011: Sanofi-Aventis Completes Acquisition of Genzyme Corporation | |
| Exhibit 99.4 | Press release dated April 12, 2011: Lixisenatide Significantly Reduces HbA1c without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas | |
| Exhibit 99.5 | Press release dated April 14, 2011: Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: April 20, 2011 | SANOFI-AVENTIS |
|||||||||
| By | /S/ John Felitti |
|||||||||
| Name: | John Felitti | |||||||||
| Title: | Associate Vice President, Corporate Law, Financial & Securities Law |
|||||||||
3
Exhibit Index
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press release dated April 5, 2011: Data from Two Mipomersen Phase 3 Trials Presented at ACC | |
| Exhibit 99.2 | Press release dated April 7, 2011: Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy of Neurology | |
| Exhibit 99.3 | Press release dated April 8, 2011: Sanofi-Aventis Completes Acquisition of Genzyme Corporation | |
| Exhibit 99.4 | Press release dated April 12, 2011: Lixisenatide Significantly Reduces HbA1c without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas | |
| Exhibit 99.5 | Press release dated April 14, 2011: Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease | |
4